Introduction
============

Platinum-based two-drug combination chemotherapy is currently the first-line chemotherapy regimen for non-small cell lung cancer (NSCLC) ([@b1-ol-0-0-6649]). Platinum would be hydrolysed in the tumor cells and form DNA-platinum complex, which prevents the DNA replication to exert cytotoxic effects. However, the resistance of tumor cells against cisplatin would seriously influence the treatment efficacy for NSCLC. Up to now, nucleotide excision repair (NER) has been recognized as one of the important mechanisms for the cisplatin resistance, in which excision repair cross-complementation 1 (ERCC1) is known to be critically involved.

ERCC1 is a single-strand DNA endonuclease, which is located on the 19q13.2 chromosome in human beings. ERCC1 is the rate-limiting enzyme for the NER pathway, which plays an important role in the DNA repairing process. The expression level of ERCC1 reflects the DNA repair capability (DRC). Downregulated DRC expression delays the DNA repairing process and results in increased susceptibility to lung cancers. In contrast, overexpression of ERCC1 contributes to the repairing of DNA-platinum complex, leading to platinum resistance. At present, retrospective clinical studies concerning ERCC1 mainly focus on NSCLC patients at advanced stage and/or after surgery. Due to the differences in experimental design and result evaluation, it is still controversial for the effects of ERCC1 expression on the prognosis of NSCLC ([@b2-ol-0-0-6649]--[@b5-ol-0-0-6649]). Several studies show that the expression of ERCC1 can be used as a predictor for the sensitivity to cisplatin ([@b6-ol-0-0-6649]--[@b9-ol-0-0-6649]). The mRNA level of ERCC1 in the tumor tissue from patients with advanced NSCLC has been shown to be closely associated with the response to the two-drug combination chemotherapy ([@b10-ol-0-0-6649]). A meta-analysis further shows that ERCC1 is the important indicator for the response rate of patients with advanced NSCLC to platinum and the overall survival (OS) rate ([@b11-ol-0-0-6649]).

The p38 signaling pathway is an important branch of the MAPK pathway, which is involved in various physiological processes, including inflammation, cell proliferation, and apoptosis ([@b12-ol-0-0-6649]). As stress signals, chemotherapeutic drugs can activate the p38 signaling pathway in a variety of tumor cells. The p38 signaling pathway has been shown to be closely related to the resistance of tumors, and its inhibitor could enhance the tumor sensitivity to chemotherapeutic agents ([@b13-ol-0-0-6649],[@b14-ol-0-0-6649]). The chemotherapeutic agent-activated p38 MAPK signal breaks the dynamic balance between the p38 and PERK signaling pathways to inhibit the proliferation of tumor cells and force the cells into dormancy, resulting in drug resistance ([@b15-ol-0-0-6649],[@b16-ol-0-0-6649]). Our previous study has shown that the p38 inhibitor BIRB796 could specifically suppress the function of membrane transporter ABCB1, and thereby reverse the drug resistance to chemotherapeutic agents, such as doxorubicin, paclitaxel, and vincristine ([@b17-ol-0-0-6649]).

Clinical studies concerning the advanced NSCLC patients have confirmed the association between the ERCC1 expression and the cisplatin response rate and disease prognosis. However, inconsistent findings have been obtained for the patients at stages I--III after surgery, and relationship between the p38 signaling pathway and the tumor drug resistance still needs to be elucidated. In this study, the effects of ERCC1 expression on the prognosis of NSCLC were investigated, especially concerning its association with the p38 signaling pathway.

Materials and methods
=====================

### Cell line and cell culture

Human lung carcinoma cell line A549 was purchased from ATCC. These cells were cultured with the RPMI-1640 complete medium (Gibco-BRL, Grand Island, NY, USA) containing 10% fetal calf serum (FCS), supplemented with 2.2% (w/v) sodium bicarbonate, 0.03% (w/v) L-glutamine, as well as 100 U/ml penicillin and 100 mg/ml streptomycin, in a 37°C, 5% CO~2~ incubator.

### Study subjects

Totally 343 patients with NSCLC (squamous carcinoma or adenocarcinoma) were screened in this study, who had admitted to the Affiliated Tumor Hospital, Xinjiang Medical University and received standard lung cancer resection (i.e., lobectomy and systematic mediastinal lymph node dissection), from January 1, 2010 to December 31, 2013. Inclusion criteria were as follows: i) patients with complete follow-up data; ii) patients who had not received chemotherapy before surgery; iii) patients with cancer at stage II or III who received systematic platinum-based two-drug combination chemotherapy for four cycles or radiotherapy after surgery; iv) patients with cancer at stage I who did not receive systematic chemotherapy until tumor recurrence during the follow-up period; and v) patients from whom the tumor and adjacent tissues were obtained. After screening, 140 patients were finally included in this study. Prior written and informed consent were obtained from every patient and the study was approved by the ethics review board of the Affiliated Tumor Hospital, Xinjiang Medical University.

### Post-operative follow-up

These 140 patients with NSCLC were followed up by telephone, which begun from the date of surgery and ended at Jun 1, 2015. Endpoint events included tumor recurrence and patient death. Evaluation indexes included the 1-, 2-, and 3-year disease-free survival (DFS) and OS rates.

### Immunohistochemistry

The expression of ERCC1 was detected with immunohistochemistry, according to Hubner *et al* ([@b18-ol-0-0-6649]). The tumor and adjacent tissues from NSCLC patients were obtained and cut into 5-µm sections. After dewaxing and rehydration, these sections were treated with 3% H~2~O~2~ for 20 min, followed by antigen retrieval for 10 min. After blocked with serum blocking solution at room temperature for 30 min, these sections were incubated with mouse anti-human anti-ERCC1 monoclonal antibody (1:100 dilution; ab2356; Abcam, Cambridge, MA, USA) at 4°C overnight. Then the sections were incubated with biotinylated secondary antibody at 37°C for 1 h. After washing, these sections were treated with SABC agent and subjected to DAB colorization. After hematoxylin staining, dehydration, xylene clearing, and neutral resin sealing, the sections were observed under microscope.

Immunohistochemical assessment was performed by two independent senior physicians from the Department of Pathology, according to the evaluation and scoring criteria from Planchard *et al* ([@b19-ol-0-0-6649]). Five fields with high magnification (×400) were randomly selected from each section, and totally 100 cells were counted. Semi-quantitative H-score indicating the relative protein expression level was obtained as the product of the staining intensity score and the positive tumor cell percentage. For the staining intensity score: 0, negative (no staining); 1, weak positive (light yellow staining); 2, positive (dark yellow staining); and 3, strong positive (brown staining). For the positive tumor cell percentage: 0, no positive tumor cells; 0.1, 1--9%; 0.5, 10--50%, and 1.0, \>50%.

### MTT assay

Cell proliferation was assessed with the MTT assay ([@b20-ol-0-0-6649]). Briefly, cells were seeded onto 96-well plates and cultured overnight. The cells were pre-incubated with or without the p38MAPK inhibitor BIRB796 (SelleckChem, Houston, TX, USA) for 1 h and then with diamminedichloroplatinum (DDP; Sigma-Aldrich, St. Louis, MO, USA) at indicated concentrations. After 68 h, these cells were treated with 20 µl MTT (4 mg/ml) for 4 h. After the medium was discarded, 120 µl dimethylsulfoxide (DMSO) was added into each well. The absorbance at 655 nm was read by the Model 550 microplate reader (Bio-Rad, Hercules, CA, USA).

### Western blot analysis

After treatment, cells were lysed with lysis buffer. The protein concentration was determined, and protein sample was subjected to SDS-PAGE and then transferred onto the nitrocellulose membrane. After blocked with 5% non-fat milk in TBST at room temperature for 2 h, the membrane was incubated with primary antibodies against p38 (ab170099), p-p38 (ab178867), β-tubulin (ab6046) and ERCC1 (ab2356) (all from Abcam) at 4°C overnight. The membrane was then incubated with HRP-conjugated secondary antibody (1:5,000 dilution; Abcam) at room temperature for 2 h. After washing with TBST, the protein bands were visualized by the enhanced Phototope™-HRP Detection kit (Cell Signaling Technology, Beverly, MA, USA) and exposed to Kodak medical X-ray processor (Carestream Health, Rochester, NY, USA). The p38 was used as loading control.

### Quantitative real-time PCR

After treatment, total RNA was extracted with the TRIzol reagent RNA Extraction kit (Molecular Research Center, Cincinnati, OH, USA), following the manufacturer\'s instructions. The first-strand cDNA was synthesized by RevertAid™ Premium First-Strand cDNA Synthesis kit (Fermentas International Inc., Burlington, ON, Canada). The PCR primer sequences were as follows: ERCC1 forward, 5′-TGTCCAGGTGGATGTGAAAGAT-3′ and reverse, 5′-GGCCTTGTAGGTCTCCAGGTA −3′; and GAPDH forward, 5′-TGTTGCCATCAATGACCCCTT-3′ and reverse, 5′-CTCCACGACGTACTCAGCG-3′. PCR was performed on the Gene Amp PCR system 9700 (PE Applied Biosystems, Foster City, CA, USA), with the following conditions: Denaturation at 94°C for 2 min; then 95°C for 30 sec, 61°C for 30 sec, and 72°C for 1 min, for totally 30 cycles; followed by extension at 72°C for 10 min. Products were resolved and examined by 1.0% agarose gel electrophoresis. Quantitative real-time PCR was performed on the Bio-Rad CFX96™ real-time system (Applied Biosystems, Framingham, MA, USA). Relative mRNA expression levels of ERCC1 were determined with the 2^−ΔΔCt^ method.

### Statistical analysis

SPSS20.0 software was used for statistical analysis. The χ^2^ test and non-parametric Wilcoxon rank sum test were performed for the comparison of clinical data. The Kaplan-Meier analysis with Breslow test was used for the survival analysis. Cox regression model was applied for the multivariate analysis. P\<0.05 was considered as statistically significant.

Results
=======

### ERCC1 expression is elevated in NSCLC tumor tissue

To investigate the expression levels of ERCC1 in the NSCLC tumor and adjacent tissues, immunohistochemistry was performed. Positive and negative staining of ERCC1 in the tissues from NSCLC (squamous carcinoma and adenocarcinoma) was shown in [Fig. 1A](#f1-ol-0-0-6649){ref-type="fig"}. The positive staining of ERCC1 was mainly located in the nucleus. The H-score assessment showed that for the tumor tissues, the median H-score was 2, which was higher than the median H-score for the adjacent tissues (0) (P\<0.01) ([Fig. 1B and C](#f1-ol-0-0-6649){ref-type="fig"}). When H-score ≥2.0 in the tumor tissue was considered as positive (i.e., the staining intensity score \>2 while the positive tumor cell percentage \>50%), the positive staining percentage for the tumor tissue was 46.4% (65/140). These results suggest that the expression level of ERCC1 is upregulated in the NSCLC tumor tissue.

### ERCC1 is associated with NSCLC pathological type, histological grade, and patient smoking status

The association between the ERCC1 expression and clinicopathological features of NSCLC was next investigated. As shown in [Table I](#tI-ol-0-0-6649){ref-type="table"}, the expression of ERCC1 is associated with the NSCLC pathological type. The expression level of ERCC1 in the squamous carcinoma (59.3%, 35/59) was significantly higher than the adenocarcinoma (37%, 30/81) (P\<0.01). Moreover, significant differences were observed in the ERCC1 expression levels between different histological stages (P\<0.05), and the expression level of ERCC1 showed an increasing trend along with the decreasing differentiation degrees. Furthermore, the expression level of ERCC1 for the smoking patients (60.3%, 41/68) was significantly higher than the non-smokers (33.3%, 24/72) (P\<0.01). On the other hand, the ERCC1 expression was not significantly associated with the other investigated clinicopathological features, including age, sex, pathological staging, T staging, N staging, and history of radio- and/or chemotherapy. These results suggest that the expression of ERCC1 is significantly associated with the NSCLC pathological type, histological grade, and patient smoking status.

### ERCC1 affects postoperative prognosis of NSCLC patients

The association between the ERCC1 expression and postoperative prognosis of NSCLC was next investigated. Our results showed that in the term of DFS, for the ERCC1-positive NSCLC patients, the 1-, 2-, and 3-year DFS rates were 79.8, 69.1, and 53.4%, respectively, with the median DFS of 22.17 m (ranging from 9.85 to 34.49 m). On the other hand, the 1-, 2-, and 3-year DFS rates for the ERCC1-negative NSCLC patients were 85.9, 76.8, and 66.8%, respectively, with the median DFS of 28.4 m (ranging from 19.34 to 37.46 m) ([Table II](#tII-ol-0-0-6649){ref-type="table"}). The Kaplan-Meier survival analysis showed that the DFS for ERCC1-negative patients was superior to the ERCC1-positive patients ([Fig. 2A](#f2-ol-0-0-6649){ref-type="fig"}). In the term of the OS, for the ERCC1-positive NSCLC patients, the 1-, 2-, and 3-year OS rates were 88.4, 67.9, and 64.7%, respectively, with the median OS of 51.93 m (ranging from 41.69 to 62.17 m). On the other hand, the 1-, 2-, and 3-year OS rates for the ERCC1-negative NSCLC patients were 94.2, 87.1, and 84.2%, respectively ([Table II](#tII-ol-0-0-6649){ref-type="table"}). The survival analysis showed that the OS for ERCC1-negative patients was superior to the ERCC1-positive patients ([Fig. 3A](#f3-ol-0-0-6649){ref-type="fig"}).

Considering the impact of other factors from the adjuvant chemotherapy, subgroup analysis was performed for the combined data of NSCLC patients at stages II--III. As shown in [Table III](#tIII-ol-0-0-6649){ref-type="table"}, no significant effects of the ERCC1 expression on DFS or OS were observed for the NSCLC patients at stage I ([Figs. 2B](#f2-ol-0-0-6649){ref-type="fig"} and [3B](#f3-ol-0-0-6649){ref-type="fig"}). For the NSCLC patients at stages II--III, no significant association was observed between the ERCC1 expression and DFS ([Fig. 2C](#f2-ol-0-0-6649){ref-type="fig"}), while the 3-year OS for ERCC1-negative patients (74.2%) was significantly higher than the ERCC1-positvie patients (56.1%) (P\<0.05) ([Fig. 3C](#f3-ol-0-0-6649){ref-type="fig"}). These results suggest that the elevated expression of ERCC1 in the NSCLC patients who need the postoperative adjuvant chemotherapy may indicate the tumor resistance.

Since the expression level of ERCC1 for the squamous carcinoma was higher than the adenocarcinoma, according subgroup analysis was further conducted. As shown in [Table IV](#tIV-ol-0-0-6649){ref-type="table"}, the 3-year DFS and OS rates for the patients with ERCC1-negative squamous carcinoma were 40.7 and 68.4%, respectively, with the median DFS of 13.63 m (ranging from 2.73 to 24.53 m). On the other hand, the 3-year DFS and OS rates for the patients with ERCC1-positie squamous carcinoma were 14.8 and 57.7%, respectively, with the median DFS of 33.63 m (ranging from 13.95 to 53.31 m). The Kaplan-Meier survival analysis showed that the DFS and OS rates of the patients with ERCC1-negative squamous carcinoma were superior to the ERCC1-positive patients (both P\<0.05) ([Figs. 2D](#f2-ol-0-0-6649){ref-type="fig"} and [3D](#f3-ol-0-0-6649){ref-type="fig"}). For the adenocarcinoma, the 3-year DFS and OS rates for the ERCC1-negative patients were 27.8 and 83.4%, respectively, with the median DFS of 27.93 m (ranging from 17.55 to 38.31 m). The 3-year DFS and OS rates for the patients with ERCC1-positive adenocarcinoma were 31.4 and 72.4%, respectively, with the median DFS of 26.27 m (ranging from 13.95 to 53.31 m). No significant effects of ERCC1 expression on the DFS and OS were observed for the patients with adenocarcinoma ([Figs. 2E](#f2-ol-0-0-6649){ref-type="fig"} and [3E](#f3-ol-0-0-6649){ref-type="fig"}). In addition, the COX regression multivariate survival analysis showed that the pathologic staging was the only independent factor affecting the patient DFS, while the pathologic staging, T staging, and ERCC1 expression were independent factors affecting the OS of NSCLC patients ([Table V](#tV-ol-0-0-6649){ref-type="table"}).

### Inhibition of p38 enhances A549 cell sensitivity to DDP and downregulates ERCC1 expression

Both p38MAPK and ERCC1 are closely related to the tumor resistance. Studies have shown that positive correlation could be observed between the ERCC1 and p-p38 levels in the NSCLC tissues ([@b21-ol-0-0-6649]). The relationship between p38MAPK and ERCC1, and its effect on the cell tumor resistance, were then investigated. Our results from the MTT assay showed that the treatment of p38 inhibitor, BIRB796, significantly enhanced the sensitivity of A549 cells to cisplatin ([Fig. 4A](#f4-ol-0-0-6649){ref-type="fig"}). The mRNA and protein expression levels of ERCC1, and the performance of the p38 signaling pathway, were then investigated. Our results showed that along with the increasing treatment concentrations of cisplatin, the mRNA and protein expression levels of ERCC1, and the level of p-p38, were gradually elevated, which could be significantly declined by the treatment of 10µmol/LBIRB796 ([Fig. 4B and C](#f4-ol-0-0-6649){ref-type="fig"}). These results suggest that the p38 signaling pathway could exert direct or indirect regulatory effects on the expression of ERCC1.

Discussion
==========

Platinum-based two-drug combined chemotherapy is an important therapeutic method for the treatment of NSCLC, however, with the overall efficiency rate of only 20--40%. With the rapid development of molecular biology in recent years, the interference of ERCC1 expression has been shown to be able to enhance the sensitivity of a variety of tumor cells to platinum drugs, including lung, colon, liver, and ovarian cancers ([@b22-ol-0-0-6649]--[@b25-ol-0-0-6649]). Olaussen *et al* ([@b26-ol-0-0-6649]) have shown that according to the immunohistochemical staining for the NSCLC patients at stages I--III after radical resection, the ERCC1-negatie patients could benefit from the platinum-based chemotherapy, while ERCC1-overexpressing patients could not. These findings suggest that ERCC1 overexpression might be associated with the platinum resistance. Sad *et al* ([@b7-ol-0-0-6649]) have investigated the chemotherapy for locally progressed NSCLC, and they suggest that the OS and progression-free survival for the ERCC1-negative patients would be longer for the ERCC1-positive patients. Hubner *et al* ([@b18-ol-0-0-6649]) have also shown that the elevated ERCC1 expression in NSCLC patients who have received platinum-based treatment would imply poor prognosis, which is however not the case for the naïve patients. Moreover, NSCLC patients overexpressing ERCC1 exhibit resistance against platinum-based therapy. Therefore, it has been accepted that the expression of ERCC1 is an important predictor for the prognosis of platinum-based chemotherapy for locally progressed lung cancer. Our results demonstrated that for the NSCLC patients after surgery, the ERCC1-negative patients have longer DFS and OS compared with the ERCC1-positive patients. Subgroup analysis showed that the OS for ERCC1-negative patients at stages II--III was significantly longer than the ERCC1-positive patients. However, no significant differences in DFS were observed between the ERCC1-negative and -positive NSCLC patients. These findings suggest that the NSCLC patients at stages II--III who receive platinum-based adjuvant chemotherapy would benefit from the negative expression of ERCC1. However, these is still no widely accepted objective criteria for the expression of ERCC1, and the majority of investigations are retrospective studies using the median split method, which would inevitably result in subjective bias in sampling, limiting its clinical application.

Our results showed that the expression levels of ERCC1 were elevated in the tumor tissues from the patients with squamous carcinoma and those had long-term smoking habit. The expression of ERCC1 in the lung squamous carcinoma tissue was significantly higher than the adenocarcinoma tissue, which was in line with the findings from Olaussen *et al* ([@b26-ol-0-0-6649]). The prognosis analysis also showed that in the patients with squamous carcinoma, the 3-year DFS and OS rates for the ERCC1-negative patients were significant higher than the ERCC1-positive patients. Moreover, the expression rate of ERCC1 was significantly higher for the long-term smoking patients than the non-smokers. Studies have shown that smoking could not only cause DNA damage and stimulate DNA repairing ([@b27-ol-0-0-6649]), but also activate p-p38 in the lung tissue of mice ([@b28-ol-0-0-6649],[@b29-ol-0-0-6649]) and induce bronchial squamous metaplasia ([@b30-ol-0-0-6649],[@b31-ol-0-0-6649]). The present study preliminarily confirmed that the p38 inhibitor could suppress the expression of ERCC1 via blocking the p38 signaling pathway. Based on these findings, we hypothesize that as exogenous stimuli, tobacco could activate the p38 signaling pathway to enhance the expression of ERCC1. Of course, further studies are still needed to confirm the hypothesis.

In conclusion, our results showed that the expression of ERCC1 in the NSCLC tumor tissue was an important indicator for the disease prognosis, especially for the patients at stages II--III who received systematic platinum-based chemotherapy. Moreover, the expression rates of ERCC1 were elevated for patients with squamous carcinoma and with smoking habit. Prognosis of ERCC1-negative patients with squamous carcinoma was superior to the ERCC1-positive patients. Furthermore, the p38 signaling pathway may directly or indirectly regulate the expression of ERCC1. These findings suggest a promising role of ERCC1 expression as the indicator for the clinical treatment and prognostic prediction of NSCLC.
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![ERCC1 expression in the NSCLC tumor and adjacent tissues. (A) Immunohistochemical staining of ERCC1 for the tissues from squamous carcinoma and adenocarcinoma. ERCC1 was localized in the nucleus. Positive staining: the staining intensity score \>2, while the positive tumor cell percentage \>50%. (B) Distribution of ERCC1 H-scores in peri-tumor and tumor tissues of 140 NSCLC patients. (C) Box diagram analyzing the ERCC1 expression in the tumor and adjacent tissues. Lower and upper limits of boxes indicate the first and third quartiles; the lines within boxes indicate the median values; and the lines extending from the boxes indicate the range of values. Compared with the adjacent tissue, \*\*P\<0.01. ERCC1, excision repair cross-complementation 1; NSCLC, non-small cell lung cancer.](ol-14-03-3463-g00){#f1-ol-0-0-6649}

![Effects of ERCC1 expression on the DFS of patients. (A) Effects of ERCC1 expression on the DFS of NSCLC patients. (B and C) Effects of ERCC1 expression on the DFS of NSCLC patients at stages I (B) and II--III (C). (D) Effects of ERCC1 expression on the DFS of patients with squamous carcinoma. (E) Effects of ERCC1 expression on the DFS of patients with adenocarcinoma. ERCC1, excision repair cross-complementation 1; NSCLC, non-small cell lung cancer; DFS, disease-free survival.](ol-14-03-3463-g01){#f2-ol-0-0-6649}

![Effects of ERCC1 expression on the OS of patients. (A) Effects of ERCC1 expression on the OS of NSCLC patients. (B and C) Effects of ERCC1 expression on the OS of NSCLC patients at stages I (B) and II--III (C). (D) Effects of ERCC1 expression on the OS of patients with squamous carcinoma. (E) Effects of ERCC1 expression on the OS of patients with adenocarcinoma. ERCC1, excision repair cross-complementation 1; NSCLC, non-small cell lung cancer; OS, overall survival.](ol-14-03-3463-g02){#f3-ol-0-0-6649}

![Effects of p38 inhibition on the A549 cell sensitivity to DDP and the ERCC1 expression. (A) Proliferation of A549 cells treated with DDP or DDP+BIRB796 (10 µmol/l) was assessed with the MTT assay. (B and C) A549 cells were treated with 10 µmol/l BIRB796 for 1 h, followed by DDP treatment at indicated concentrations for 24 h. The mRNA expression level (B) of ERCC1, as well as the protein expression levels (C) of p38, p-p38, and ERCC1 were detected with western blot analysis and real-time PCR, respectively. Compared with the control group, \*P\<0.01. DDP, diamminedichloroplatinum; ERCC1, excision repair cross-complementation 1.](ol-14-03-3463-g03){#f4-ol-0-0-6649}

###### 

Relationship between the ERCC1 expression in tumor tissue and clinicopathological features of NSCLC.

                                   Tumor ERCC1 expression                       
  -------------------- ----------- ------------------------ ----------- ------- -------
  Age (years)                                                           5.596   0.061
    \<50               20 (14.3)   14 (70.0)                6 (30.0)            
    50--70             95 (67.8)   39 (41.0)                56 (59.0)           
    \>70               25 (17.9)   12 (48.0)                13 (52.0)           
  Sex                                                                   0.161   0.689
    Male               88 (62.9)   42 (47.7)                46 (52.3)           
    Female             52 (37.1)   23 (44.2)                29 (55.8)           
  Histological type                                                     6.816   0.009
    Squamous cancer    59 (42.1)   35 (59.3)                24 (40.7)           
    Adenocarcinoma     81 (57.9)   30 (37.0)                51 (63.0)           
  Histological grade                                                    7.665   0.022
    G1                 59 (42.1)   35 (59.3)                24 (40.7)           
    G2                 57 (40.7)   23 (40.4)                34 (59.6)           
    G3                 24 (17.2)   7 (29.2)                 17 (70.8)           
  pTNM                                                                  2.094   0.351
    Stage I            50 (35.7)   23 (46.0)                27 (54.0)           
    Stage II           35 (25.0)   13 (37.1)                22 (62.9)           
    Stage III          55 (39.3)   29 (52.7)                26 (47.3)           
  T stage                                                               1.264   0.532
    T1                 34 (24.2)   16 (47.1)                18 (52.9)           
    T2                 81 (57.9)   35 (43.2)                46 (56.8)           
    T3                 25 (17.9)   14 (56.0)                11 (44)             
  N stage                                                               1.129   0.569
    N0                 74 (52.9)   33 (44.6)                41 (55.4)           
    N1                 18 (12.9)   7 (38.9)                 11 (61.1)           
    N2                 48 (34.2)   25 (52.1)                23 (47.9)           
  Smoking status                                                        10.22   0.001
    Non-smoker         72 (51.4)   24 (33.3)                48 (66.7)           
    Smoker             68 (48.6)   41 (60.3)                27 (39.7)           
  Chemoradiotherapy                                                     0.838   0.36
    No                 61 (43.6)   31 (50.8)                30 (49.2)           
    Yes                79 (56.4)   34 (43.0)                45 (57.0)           

Smokers were defined as patients with the smoking habit for 10 years (10 cigarettes/day). ERCC1, excision repair cross-complementation 1; NSCLC, non-small cell lung cancer.

###### 

Prognostic analysis of the tumor ERCC1 expression in NSLCL patients.

                                                  Tumor ERCC1 expression                                  
  ------------------------- --------------------- ------------------------ ---------------------- ------- -------
  DFS                                                                                             4.758   0.029
  Recurrence/total, n       78/140                37/65                    41/75                          
    1 year DFS rate         70.9%                 79.8%                    85.9%                          
    2 years DFS rate        51.0%                 69.1%                    76.8%                          
    3 years DFS rate        33.7%                 53.4%                    66.8%                          
    Median DFS, m (95%CI)   24.57 (19.6--29.54)   22.17 (9.85--34.49)      28.40 (19.34--37.46)           
  OS                                                                                              6.502   0.011
  Death/total, n            30/140                19/65                    11/75                          
    1 year OS rate          97.7%                 88.4%                    94.2%                          
    2 years OS rate         92.3%                 67.9%                    87.1%                          
    3 years OS rate         89.8%                 64.7%                    84.2%                          
    Median OS, m (95%CI)    --                    51.93 (41.686--62.174)   --                             

ERCC1, excision repair cross-complementation 1; NSCLC, non-small cell lung cancer; DFS, disease-free survival; OS, overall survival.

###### 

Prognostic analysis of the tumor ERCC1 expression in NSLCL patients at stages I and II--III.

                                                     Tumor ERCC1 expression                                   
  ------------------------- ------------------------ ------------------------ ----------------------- ------- -------
  Stage I                                                                                                     
  Recurrence/total, n       17/50                    8/23                     9/27                    3.143   0.076
    3-years DFS rate        59.7%                    41.7%                    69.0%                           
    Median DFS, m (95%CI)   40.97 (35.213--46.727)   35.4 (12.702--58.098)    52.03                           
  Death/total, n            4/50                     2/23                     2/27                    2.180   0.140
    3-years OS rate         85.8%                    82.6%                    90.0%                           
    Median OS, m (95%CI)    --                       --                       --                              
  Stage II--III                                                                                               
  Recurrence/total, n       61/90                    29/42                    32/48                   2.869   0.090
    3-years DFS rate        19.9%                    12.9%                    21.8%                           
    Median DFS, m (95%CI)   15.67 (9.122--22.218)    11.1 (3.972--18.228)     18.6 (11.762--25.438)           
  Death/total, n            26/90                    17/42                    9/48                    5.001   0.025
    3-years OS rate         64.7%                    56.1%                    74.2%                           
    Median OS, m (95%CI)    51.93(22.646--81.214)    --                       --                              

ERCC1, excision repair cross-complementation 1; NSCLC, non-small cell lung cancer; DFS, disease-free survival; OS, overall survival.

###### 

Prognostic analysis of the tumor ERCC1 expression in patients with squamous carcinoma and adenocarcinoma.

                                                    Tumor ERCC1 expression                                   
  ------------------------- ----------------------- ------------------------ ----------------------- ------- -------
  Squamous carcinoma                                                                                         
  Recurrence/total, n       37/59                   23/35                    14/24                   4.042   0.044
    3-years DFS rate        28.1%                   14.8%                    40.7%                           
    Median DFS, m (95%CI)   21.70(10.611--32.789)   33.63(13.948--53.312)    13.63(2.731--24.529)            
  Death/total, n            17/59                   13/35                    4/24                    3.948   0.047
    3-years OS rate         69.8%                   57.7%                    68.4%                           
    Median OS, m (95%CI)    51.93(41.686--62.174)   --                       --                              
  Adenocarcinoma                                                                                             
  Recurrence/total, n       41/81                   14/30                    27/51                   0.006   0.938
    3-years DFS rate        29.8%                   31.4%                    27.8%                           
    Median DFS, m (95%CI)   27.77(21.861--33.679)   26.27(13.948--53.312)    27.93(17.549--38.311)           
  Death/total, n            13/81                   6/30                     7/51                    0.97    0.325
    3-years OS rate         79.1%                   72.4%                    83.4%                           
    Median OS, m (95%CI)    --                      --                       --                              

ERCC1, excision repair cross-complementation 1; DFS, disease-free survival; OS, overall survival.

###### 

COX regression multivariate survival analysis for NSCLC patients.

                                                               95.0% CI for Exp(β)   
  ----- --------- ------- ------- -------- --- ------- ------- --------------------- -------
  DFS   pTNM      0.747   0.146   26.304   1   0.000   2.110   1.586                 2.807
  OS    pTNM      0.972   0.293   11.042   1   0.001   2.644   1.490                 4.691
        T stage   0.402   0.199   4.057    1   0.044   1.494   1.011                 2.209
        ERCC1     0.803   0.385   4.352    1   0.037   2.231   1.050                 4.742

ERCC1, excision repair cross-complementation 1; NSCLC, non-small cell lung cancer; DFS, disease-free survival; OS, overall survival.

[^1]: Contributed equally
